| NCT06781983 | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-01-24 | 2029-04 | 2028-04 |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | RECRUITING | PHASE1, PHASE2 | 2024-03-04 | 2028-12-31 | 2028-12-31 |
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | RECRUITING | PHASE2 | 2023-06-23 | 2026-09 | 2025-06 |
| NCT05321147 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | COMPLETED | PHASE1 | 2022-03-17 | 2024-02-08 | 2023-11-19 |
| NCT03902184 | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-05-22 | 2026-01-31 | 2023-10-31 |
| NCT03665129 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors | TERMINATED | PHASE1 | 2018-09-07 | 2021-02-24 | 2021-02-24 |
| NCT02643550 | Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | COMPLETED | PHASE1, PHASE2 | 2015-12 | 2023-03-28 | 2023-03-28 |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | TERMINATED | PHASE1, PHASE2 | 2015-11-09 | 2019-09-25 | 2018-10-29 |
| NCT02593045 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | COMPLETED | PHASE1 | 2015-10 | 2020-04 | 2020-04 |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | TERMINATED | PHASE1, PHASE2 | 2014-12 | 2016-12 | 2016-12 |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) | COMPLETED | PHASE2 | 2012-10 | 2016-11-17 | 2016-11-17 |
| NCT01370902 | Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2011-05 | 2014-03 | 2014-03 |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma | COMPLETED | PHASE2 | 2010-09 | 2013-01 | 2012-07 |
| NCT01217203 | Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse | COMPLETED | PHASE1 | 2010-09 | 2014-02 | 2013-12 |
| NCT00999830 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma | COMPLETED | PHASE2 | 2009-09 | 2013-06 | 2012-06 |
| NCT00552396 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma | COMPLETED | PHASE1 | 2007-05 | 2011-01 | 2011-01 |
| NCT01256073 | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia | COMPLETED | PHASE1 | 2007-02 | 2013-09 | 2013-07 |